January 29, 2019 11:09 AM EST

Aldeyra bags PhIII-ready eye drug in Helio buyout; Liquid biopsy maker OncoCyte shares skyrocket on validation data

ENDPOINTS

→ Eye drug developer Aldeyra Therapeutics $ALDX, which counts J&J $JNJ as a partner, has bought private biotech Helio Vision for $10 million upfront …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aldeyra bags PhIII-ready eye drug in Helio buyout; Liquid biopsy maker OncoCyte shares skyrocket on validation data

ENDPOINTS

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Aldeyra bags PhI­II-ready eye drug in He­lio buy­out; Liq­uid biop­sy mak­er On­co­Cyte shares sky­rock­et on val­i­da­tion da­ta

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Aldeyra bags PhIII-ready eye drug in Helio buyout; Liquid biopsy maker OncoCyte shares skyrocket on validation data